Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolinapant with RT/CRT in Preoperative Rectal Cancer
NCT05912075Phase 1Recruiting
- Sponsor
- Gustave Roussy
- Start
- Dec 2023
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tolinapant in rectal cancer, sponsored by Gustave Roussy. Primary endpoint: Dose-limiting toxicities at 10 weeks. Started Dec 2023; status: recruiting.
02
Drugs
tolinapant
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05912075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05912075.